Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Current Assets (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Current Assets for 11 consecutive years, with $22.6 million as the latest value for Q3 2025.

  • Quarterly Current Assets rose 126.22% to $22.6 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $22.6 million through Sep 2025, up 126.22% year-over-year, with the annual reading at $10.7 million for FY2024, 44.09% down from the prior year.
  • Current Assets hit $22.6 million in Q3 2025 for Aptevo Therapeutics, up from $11.1 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $65.8 million in Q2 2021 to a low of $3.6 million in Q1 2025.
  • Historically, Current Assets has averaged $28.2 million across 5 years, with a median of $22.7 million in 2023.
  • Biggest five-year swings in Current Assets: soared 527.05% in 2021 and later plummeted 70.13% in 2025.
  • Year by year, Current Assets stood at $52.6 million in 2021, then crashed by 47.78% to $27.4 million in 2022, then tumbled by 30.54% to $19.1 million in 2023, then tumbled by 44.09% to $10.7 million in 2024, then soared by 112.49% to $22.6 million in 2025.
  • Business Quant data shows Current Assets for APVO at $22.6 million in Q3 2025, $11.1 million in Q2 2025, and $3.6 million in Q1 2025.